Keymed Biosciences, Inc.HKEX: 2162

Inside information announcement-(1) update on product revenue for the first three quarters of 2026 and (2) national medical products administration approves the new indication marketing application for Stapokibart for the treatment of moderate-to-severe atopic dermatitis in adolescents

· Issued by Keymed Biosciences, Inc. via HKEXnews

Filed with HKEX · Stock code 2162 · · 3 pages · English

Summary by 6ix AI

Additionally, the National Medical Products Administration has approved a new indication for Stapokibart, allowing its use in treating moderate-to-severe atopic dermatitis in adolescents. The announcement highlights the company's expanding commercialization efforts and the positive outcomes from clinical studies supporting Stapokibart's efficacy and safety.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/inside-information-announcement-1-update-on-product-revenue-for-the-first-three-quarters-of-2026-and-2-national-medical-products-administration-approves-the-new-indication-marketing-application-for-stapokibart-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adolescents

Keymed Biosciences, Inc. on 6ix

Earlier from Keymed Biosciences

All Keymed Biosciences news releases